A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes
Latest Information Update: 02 Sep 2024
At a glance
- Drugs Azacitidine (Primary)
- Indications Myelodysplastic syndromes
- Focus Registrational; Therapeutic Use
- Acronyms QUAZAR
- Sponsors Celgene Corporation
- 24 Jan 2024 Status changed from active, no longer recruiting to completed.
- 12 Jan 2024 This trial has been Completed in Norway, According to European Clinical Trials Database record.
- 10 Jan 2024 The trial has been completed in Netherlands , according to European Clinical Trials Database record.